Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Villunger

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Oncology Research|June 15, 1999
Does "death receptor" signaling play a role in tumorigenesis and cancer therapy?A Villunger, A Strasser
Leukemia & Lymphoma|January 28, 1999
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a modelR Greil, A Egle, A Villunger
Oncogene|July 31, 2009
Noxa: at the tip of the balance between life and deathC Ploner, R Kofler, A Villunger
Oncogene|July 8, 2009
Caspase-2: killer, savior and safeguard--emerging versatile roles for an ill-defined caspaseG Krumschnabel, C Manzl, A Villunger
Cell Death & Disease|September 7, 2018
Correction to: The BH3-only protein Bad is dispensable for TNF-mediated cell deathE Ottina, M Sochalska, R Sgonc, et al.
Cell Death and Differentiation|March 29, 2008
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?V Labi, F Grespi, F Baumgartner, et al.
Cell Death and Differentiation|April 29, 2006
BH3-only proteins in cell death initiation, malignant disease and anticancer therapyV Labi, M Erlacher, S Kiessling, et al.
Cell Death and Differentiation|July 14, 2007
How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?A Olsson, C Manzl, A Strasser, et al.
Cell Death & Disease|March 3, 2011
Bcl-2-regulated cell death signalling in the prevention of autoimmunityD Tischner, C Woess, E Ottina, et al.
The Journal of Biological Chemistry|July 25, 2000
Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iotaM Spitaler, A Villunger, H Grunicke, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Oncology Research|June 15, 1999
Does "death receptor" signaling play a role in tumorigenesis and cancer therapy?A Villunger, A Strasser
Leukemia & Lymphoma|January 28, 1999
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a modelR Greil, A Egle, A Villunger
Oncogene|July 31, 2009
Noxa: at the tip of the balance between life and deathC Ploner, R Kofler, A Villunger
Oncogene|July 8, 2009
Caspase-2: killer, savior and safeguard--emerging versatile roles for an ill-defined caspaseG Krumschnabel, C Manzl, A Villunger
Cell Death & Disease|September 7, 2018
Correction to: The BH3-only protein Bad is dispensable for TNF-mediated cell deathE Ottina, M Sochalska, R Sgonc, et al.
Cell Death and Differentiation|March 29, 2008
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?V Labi, F Grespi, F Baumgartner, et al.
Cell Death and Differentiation|April 29, 2006
BH3-only proteins in cell death initiation, malignant disease and anticancer therapyV Labi, M Erlacher, S Kiessling, et al.
Cell Death and Differentiation|July 14, 2007
How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?A Olsson, C Manzl, A Strasser, et al.
Cell Death & Disease|March 3, 2011
Bcl-2-regulated cell death signalling in the prevention of autoimmunityD Tischner, C Woess, E Ottina, et al.
The Journal of Biological Chemistry|July 25, 2000
Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iotaM Spitaler, A Villunger, H Grunicke, et al.
Pageof 6